Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01941082 · ClinicalTrials.gov registry record · Phase 1
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01941082 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 24 participants.
The verdict
NCT01941082, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration.
Interventions
- DRUG RO6867461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01941082
The ClinicalTrials.gov registry entry for NCT01941082 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO6867461 is the first listed.
NCT01941082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01941082 about?
NCT01941082 is a clinical study titled "A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration". This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration.
What is the current status of trial NCT01941082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-12. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01941082?
The interventions under investigation include: RO6867461 (DRUG).
Who is sponsoring clinical trial NCT01941082?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.